Partner, BDC Canada
joined DBC in 2007 and is a partner in the Health Venture Fund. She brings over 20 years of management, entrepreneurial, and consulting experience in the biopharmaceutical industry.
She is currently serving on the boards of several BDC portfolio companies including: Alethia Biotherapeutics, a preclinical company focused on the development of MAbs for novel disease targets; Cytochroma, a clinical stage specialty pharmaceutical company treating the clinical consequences of secondary hyperparathyroidism and vitamin D insufficiency in patients with chronic kidney disease; Leap Medical, developing a technology to non-invasively detect and monitor brain injury and disease; and, Milestone Pharmaceuticals, a cardiovascular company developing a “pill-in-the-pocket” for patients to manage their disease at home and avoid the hospital setting.
Prior to joining BDC, she was Chief Operating Officer and held the position of Vice President in clinical, regulatory affairs, and product strategy for various biotech companies, as well as Senior Vice President for a public pharmaceutical company. Ela’s diversified background also includes key involvement in product acquisition and M & A activities.